Hadassah

Hadassah and Boston Cardiologists Identify Factor Which Exacerbates Heart Failure

Thursday, Sep 27 2012

In a series of experiments, Dr. Ronen Beeri, Director of the Cardiovascular Research Center at the Hadassah Medical Center, and Dr. Robert Levine, Senior Physician at Massachusetts General Hospital in Boston, have demonstrated that mitral regurgitation augments the remodeling process occurring after a myocardial infraction which, in turn, exacerbates further heart failure.

They have also discovered that repairing the mitral regurgitation early enough may reverse these deleterious processes, while delayed repair may not. The two physicians have now begun to explore the cellular processes which cause the individual cells to fail. In what may hold promise for the future, they have utilized gene therapy techniques in a sheep model of heart failure to implant a gene for the Sarcoplasmic reticulum Ca (+2)-ATPase ( SERCA2a), which controls a key process in the cell's calcium signaling. The sheep which underwent gene therapy had upregulated levels of SERCA2a, which led to better function and lesser remodeling. They exhibited improved contractility, smaller heart volumes, and activation of cellular pathways that lead to better heart compensation.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, May 23 2018

From Legacy to Innovation: The Vision of Hadassah’s New Division of Nursing Director

Rely Alon, PhD, the new director of the Hadassah Medical Organization’s Division of Nursing and Health Professions, has a vision: “to bring Hadassah’s nurses to the forefront of leadership and to the spearhead of nursing in Israel.”

READ MORE ›
alt_text

Monday, May 7 2018

Hadassah Cardiac Specialists Are Collaborating with Colleagues to Save Syrian Children

In an effort to save the lives of Syrian children suffering from life-threatening and complex heart abnormalities, the Hadassah Medical Organization and the Baruch Padeh Medical Center in Poriya-Tiberias have launched a unique collaboration as part of the Israel Defense Forces’ Good Neighbor program.

READ MORE ›
alt_text

Monday, May 7 2018

Pluristem Stem Cell Therapy, Based on Hadassah Preclinical Research, Has Been Cleared by FDA

Pluristem Therapeutics has announced that its new cell therapy to treat acute radiation syndrome (PLX-R18), based on the pioneering studies performed within the laboratory of Prof. Raphael Gorodetsky at the Hadassah Medical Organization, has received clearance from the United States Food and Drug Administration to treat individuals who may have been acutely exposed to high-dose radiation as the result of a nuclear attack or accident.

READ MORE ›
alt_text

Thursday, May 3 2018

HMO Exclusive Call with Nurse Rely Alon

Please join us for an exclusive conference call with Dr. Rely Alon, Director, Division of Nursing & Health Professions, Wednesday May 9, 2018 from 10:00 - 11:00 am EDT

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More